TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2704504
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg conjugated equine estrogen (Premarin) + 5 mg medroxyprogesterone acetate (Provera)
Study: 2704504
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (Premarin) + placebo
Study: 2704504
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg conjugated equine estrogen (Premarin) + placebo
Study: 407817
Drug: Oral cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cromolyn therapy
Study: 31321541
Drug: CGRP-targeted treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP-targeted treatments
Study: 27761732
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vaginal progesterone suppository twice daily
Study: 27761732
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral dydrogesterone twice daily
Study: 27761732
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral dydrogesterone twice daily combined with 0.1 mg GnRH‐α
Study: 27761732
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral dydrogesterone twice daily combined with 1500 IU hCG
Study: 25345840
Drug: Intralesional bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intralesional bevacizumab with antiretroviral therapy
Study: 25345840
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy alone (Control)
Study: 23539110
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) dosing strategy
Study: 21594828
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration (Hep [+])
Study: 21594828
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin administration (Hep [‐])
Study: 19155456
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 to 20 mg/d for 12 weeks)
Study: 11277342
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor therapy (enalapril maleate, imidapril hydrochloride, trandolapril)
Study: 27743129
Drug: 4-h Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h Oral Fat Tolerance Test (OFTT) without prior exercise
Study: 27743129
Drug: 4-h Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h Oral Fat Tolerance Test (OFTT) with 1-h prior aerobic exercise
Study: 27093772
Drug: Oral-B 3D
Normalized name: Oral-B 3D White Luxe Pulsar Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B 3D White Radiant
Study: 25300874
Drug: Multicomponent online
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent online sleep intervention (sleep information, sleep hygiene education, cognitive behavioral therapy)
Study: 17576075
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction by audiotape
Study: 17576075
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction live
Study: 8416406
Drug: Full-strength acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-strength acellular pertussis vaccine (40 micrograms of pertussis proteins)
Study: 8416406
Drug: Half-strength acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-strength acellular pertussis vaccine
Study: 8416406
Drug: Quarter-strength acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-strength acellular pertussis vaccine
Study: 8416406
Drug: Standard adult
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adult tetanus-diphtheria vaccine alone
Study: 3816923
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg controlled release (CR) tablets of salbutamol b.d.
Study: 3816923
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg conventional tablets of salbutamol a.i.d.
Study: 31975122
Drug: VEPTR surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEPTR surgery with administration of preoperative antibiotics more than 30 minutes before surgery (or >60 minutes for vancomycin)
Study: 31975122
Drug: VEPTR implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEPTR implant surgeries
Study: 10657270
Drug: Inhaled carbon
Normalized name: carbon dioxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled carbon dioxide (CO2)
Study: 8866596
Drug: Dose‐titrated slow‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐titrated slow‐release theophylline capsules ('Theo‐Dur') b.i.d. (n=97)
Study: 29861050
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) with normal PTF‐V1
Study: 29861050
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) with abnormal PTF‐V1
Study: 17656473
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements with IDPN
Study: 17656473
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements without IDPN
Study: 17656473
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in prealbumin >30 mg/L within 3 months
Study: 11870174
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant interferon alfa-2b (IFNα2b)
Study: 10192568
Drug: Drain kept
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drain kept until discharge had decreased to less than 35 ml/24 hours
Study: 7491817
Drug: PFP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFP vaccine
Study: 7491817
Drug: TIV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV vaccine (control)
Study: 2176794
Drug: pH-adjusted 1.73%
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-adjusted 1.73% lidocaine (1 ml of NaHCO3 44.6 meq/L added to 10 ml of 2% lidocaine hydrochloride)
Study: 21356042
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (warfarin for 6 months followed by antiplatelet agents)
Study: 11419834
Drug: IFN-alpha-2A (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha-2A (subcutaneous injections)
Study: 3816835
Drug: Labetalol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (loading dose followed by slow intravenous infusion over six hours, then oral therapy for five days, adjusted to maintain systolic pressure 100-120 mmHg)
Study: 29336835
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (77 Gy in 35 fractions)
Study: 29336835
Drug: Dose-escalated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated treatment (77 Gy in 35 fractions + integrated boost up to 95 Gy)
Study: 24278929
Drug: Osstem TSIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osstem TSIII HA implants (4.5 or 5.0 mm diameter, 10 mm long)
Study: 24278929
Drug: Zimmer TSV
Normalized name: BINDER,ABDOMINAL,10IN ZIMMER #2732-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimmer TSV implants (4.7 mm diameter, 10 mm long)
Study: 18219661
Drug: Gefitinib (treatment)
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib (treatment)
Study: 18219661
Drug: Zymed antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zymed antibody (treatment)
Study: 10351414
Drug: New medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: New medication for osteoarthritis
Study: 7743286
Drug: 5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lignocaine ointment applied to the heel under an occlusive dressing for one hour before heel prick
Study: 7138632
Drug: Potassium and
Normalized name: Potassium and/or potassium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium and magnesium aspartate (K + Mg Asp) - 7.2 g administered during a 24 h period prior to work
Study: 7138632
Drug: Potassium and
Normalized name: Potassium and/or potassium compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium and magnesium aspartate (K + Mg Asp)
Study: 30633959
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) 50 ppm for 24 hours
Study: 26591552
Drug: Pioglitazone as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone as part of combination therapy for 3 months
Study: 21528639
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg (test formulation)
Study: 19358416
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with a cytotoxic platinum agent
Study: 19358416
Drug: Cytotoxic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agents alone
Study: 12507703
Drug: ADL 10‐0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADL 10‐0101 (peripherally selective KOR agonist)
Study: 9011784
Drug: Multiple-allergen immunotherapy
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-allergen immunotherapy (subcutaneous injections of a mixture of up to seven aeroallergen extracts)
Study: 9011784
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous injections of placebo)
Study: 9011784
Drug: Multiple-allergen immunotherapy
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-allergen immunotherapy
Study: 3124427
Drug: Doxycycline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (400 mg in a single dose)
Study: 3124427
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g given twice with an 8-hour interval)
Study: 30541221
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg) 20 min before anesthesia induction, followed by 0.2 μg·kg(‐1)·h(‐1) intraoperatively.
Study: 30541221
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 μg·kg(‐1)·h(‐1)) plus sufentanil (0.025 μg·kg(‐1)·h(‐1)) for PCA in group D.
Study: 25412051
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block with catheter placement and continuous infusion
Study: 24694531
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg Q2W
Study: 24694531
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg QM
Study: 23713082
Drug: BAY 94‐8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 94‐8862 (5-10 mg/day)
Study: 23713082
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 or 50 mg/day)
Study: 19132268
Drug: Agaricus sylvaticus
Normalized name: AGARICUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agaricus sylvaticus fungus (30 mg/kg/day)
Study: 29770722
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 0.1% ointment
Study: 16629794
Drug: Cetomacrogol ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetomacrogol ointment (placebo)
Study: 14636982
Drug: Artesunate alone
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate alone (50 mg rectal capsules, 40 mg/kg total dose over 6 days)
Study: 14636982
Drug: Artesunate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (20 mg/kg total dose on day 1)
Study: 14636982
Drug: Artesunate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (15-17 mg/kg total dose on days 1 and 3)
Study: 8672384
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine and adrenaline 1/200,000 (B+E) 8 ml before incision and saline 8 ml after incision
Study: 8672384
Drug: Saline 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 8 ml before incision and B+E 8 ml after incision
Study: 8672384
Drug: Saline 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 8 ml before and after incision
Study: 30689969
Drug: Trial group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial group with additional intraoperative splint for verification of implants' angulation
Study: 12858407
Drug: Anti-HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HCV treatment in HIV-coinfected patients
Study: 9796763
Drug: Colchicine treatment
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine treatment for 8 weeks
Study: 19863619
Drug: FPV 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 1400 mg bid with TDF 300 mg qd
Study: 19863619
Drug: FPV/RTV 700/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV/RTV 700/100 mg bid with TDF 300 mg qd
Study: 19863619
Drug: FPV 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV 1400 mg bid without TDF
Study: 19863619
Drug: FPV/RTV 700/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPV/RTV 700/100 mg bid without TDF
Study: 12893904
Drug: Undiluted direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted direct injection of ferumoxides (0.56 mg of iron per kg of body weight, administered during 2 minutes at 2 mL/min)
Study: 12893904
Drug: Diluted slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted slow infusion of ferumoxides (administered during 30 minutes)
Study: 12893904
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (direct injection and slow infusion)
Study: 10589310
Drug: teacher/self-preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: teacher/self-preparation
Study: 10589310
Drug: nurse/self-preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: nurse/self-preparation
Study: 9005789
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg intravenous followed by 400 mg oral once a day for at least 14 days
Study: 9005789
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg oral once a day
Study: 9005789
Drug: Ofloxacin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (various regimens: 200 mg thrice a day, 200 mg twice a day, 400 mg once a day)
Study: 6781586
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 (low dose)
Study: 6781586
Drug: 500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 (medium dose)
Study: 6781586
Drug: 5 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/m2 (high dose)
Study: 6781586
Drug: Cross-over to
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over to higher dose
Study: 6781586
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who completed first four treatments
Study: 31622456
Drug: Early ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ART initiation during TB treatment
Study: 31622456
Drug: Late ART
Normalized name: Flavor PCCA Chocolate Artificial (Aldehyde Base)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late ART initiation during TB treatment
Study: 31622456
Drug: Sequential ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential ART initiation after TB treatment completion
Study: 23522530
Drug: Phentolamine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine administered at 30 minutes after IAN block
Study: 23522530
Drug: Phentolamine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine administered at 60 minutes after IAN block
Study: 23522530
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection at 30 minutes and phentolamine at 60 minutes
Study: 19267842
Drug: Topical hyaluronic
Normalized name: hyaluronate Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hyaluronic acid (HA) gel preparation (0.2%)
Study: 14744178
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 to 20 mg/day, most receiving 5 to 10 mg/day)
Study: 11099053
Drug: 50 microg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/ml hr-EGF
Study: 11099053
Drug: 10 microg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/ml hr-EGF
Study: 8445427
Drug: Intensive systemic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systemic therapy with either IT MTX or CXRT
Study: 8445427
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy with CXRT
Study: 8445427
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy with IT MTX
Study: 8445427
Drug: CXRT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXRT in patients 10 years or older with intensive systemic therapy
Study: 8445427
Drug: IT MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT MTX in patients 10 years or older with intensive systemic therapy
Study: 8445427
Drug: IT MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT MTX in patients less than 10 years of age with intensive systemic therapy
Study: 8445427
Drug: CXRT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXRT in patients less than 10 years of age with intensive systemic therapy
Study: 29788996
Drug: Guided web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided web-based intervention with treatment as usual and immediate access to the web-based intervention
Study: 29788996
Drug: Waiting control
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting control condition with treatment as usual and delayed access to the web-based intervention
Study: 27338551
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine spray (group L)
Study: 22759255
Drug: SGP‐HA (≤1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGP‐HA (≤1.5 mL/lip)
Study: 20041473
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) with quinidine pre-treatment
Study: 17922883
Drug: MDI +
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI + SP (metered dose inhaler plus spacer)
Study: 31232920
Drug: CCR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCR with PBM Therapy (CR-PBM)
Study: 31232920
Drug: CCR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCR and placebo PBM Therapy (CR-PlaceboPBM)
Study: 28715325
Drug: Inference-based framework
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inference-based framework for privacy-preserving similarity search in Hamming space; specific dosage and duration not applicable.
Study: 26968623
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (investigational drug)
Study: 26968623
Drug: Control drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug (mometasone furoate)
Study: 18269128
Drug: Chloroform (CHCl3)
DrugBank: Chloroform (DB11387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroform (CHCl3) treatment
Study: 18269128
Drug: Chloroform (CHCl3)
DrugBank: Chloroform (DB11387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroform (CHCl3) + Silane (sil) treatment
Study: 18269128
Drug: Sandblasting (sand)
Normalized name: SAND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasting (sand) + Silane (sil) treatment
Study: 18269128
Drug: Silane (sil)
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silane (sil) treatment
Study: 12191661
Drug: Scotchbond 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scotchbond 1 in combination with Rely X ARC resin cement (3M)
Study: 1087955
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both regimens
Study: 31623611
Drug: Processed red
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Processed red meat with high drinking water nitrate (3.7 mg/kg bodyweight)
Study: 31623611
Drug: Unprocessed white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unprocessed white meat with high drinking water nitrate (3.7 mg/kg bodyweight)
Study: 27654259
Drug: Metformin (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (conventional antidiabetic doses)
Study: 24463451
Drug: teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide (20 μg recombinant human parathyroid hormone)
Study: 20719253
Drug: Budesonide 800
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 800 μg twice daily for 12 months
Study: 16170180
Drug: Chemoradiotherapy (CRT);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT); concurrent cisplatin (25 mg/m2 on days 1 to 4) on weeks 1, 4, and 7 of RT and adjuvant cisplatin (20 mg/m2 on days 1 to 4) and fluorouracil (1,000 mg/m2 on days 1 to 4) every 4 weeks for three cycles after completion of RT